objective(s): we investigated a frequency of lower extremity uptake on the radioactive iodine (rai) whole body scan (wbs) after rai treatment in patients with differentiated thyroid cancer, in order to retrospectively examine whether or not the frequency was pathological. methods: this retrospective study included 170 patients with thyroid cancer, undergoing rai treatment. overall, 99r (58%) an...

OBJECTIVE Dosimetry studies have shown that activities of 131I as small as 10-20 MBq may cause a stunning effect. A result of this stunning effect may be a lower success rate of the ablative 131I therapy for differentiated thyroid carcinoma (DTC). The aim of this study was to determine whether pre-therapeutic uptake measurement with 40 MBq 131I causes a lower success rate of ablation. DESIGN ...

The daily administration of ƒÀ-estradiol benzoate (50ƒÊg or I mg) to hypophysectomized female rats for five consecutive days did not markedly alter 131I uptake by the thyroid gland. Estrogen or PMS increased thyroid uptake of 131I in TSH treated hypophysectomized rats. Similar results were obtained with estrogen but not PMS in hypophysectomized and oophorectomized animals. These observations sh...

Thyroid carcinoma is primarily treated by surgery combined with radioactive 131iodine (131I) treatment; however, certain patients exhibit resistance to 131I treatment. Previous research indicated that nuclear factor‑κB (NF‑κB) was associated with resistance to 131I in cancer cells. The present study aimed to investigate the effects of NF‑κB on 131I uptake and apoptosis in thyroid carcinoma cell...

Herein, folic acid (FA) conjugated Poly(d,l-lactide-co-glycolide) (PLGA)-lipid composites (FA-PL) were developed as nanocarriers for the targeted delivery of insoluble anti-cancer drug paclitaxel (PTX), resulting FA-PLP nanoparticles. Furthermore, 131I, as a radioactive tracer, was used to label FA-PLP nanoparticles (FA-PLP-131I) to evaluate their cell uptake activity, in vivo blood circulation...

Dedifferentiation of well-differentiated thyroid carcinoma is a well-known phenomenon that may lead to the disappearance of radioiodine uptake in tumors and the inability to treat patients with radioiodine. We report a patient in whom the 131I uptake progressively diminished to such low levels after a cumulative dose of 31.5 GBq that further 131I administration was considered nonbeneficial. The...

511 AYOUNG WOMAN with papillary thyroid cancer treated with total thyroidectomy, received an ablative dose (3000 MBq) of 131I. Thyroxine had been withdrawn for 4 weeks. A wholebody scan was performed 8 days after the ablative dose of 131I. The scan (Fig. 1) shows uptake in the thyroid bed caused by thyroid remnant, diffuse uptake in the liver, and uptake in both breasts. Post-131I therapy scans...

Melanoma is a tumor of continuously increasing incidence for which new methods of imaging and targeted therapy are widely sought. Radioiodinated methylene blue is a promising tracer, showing selective uptake in human pigmented melanoma cells. We performed 131I-labeling of the tracer using 1% methylene blue injection United States Pharmacopeia (USP) and 131I sodium iodide. For quality control, a...

UNLABELLED 131I-labeled metaiodobenzylguanidine (MIBG) is an established treatment modality for neuroendocrine tumors. Because of low tumor doses, it has a predominantly palliative character. Our approach was to investigate whether intraarterial application of 131I-MIBG has the potential to enhance tumor uptake. METHODS Seventeen patients with primary or metastasized neuroendocrine tumors rec...

ADRENAL-SPECIFIC RADIOLIGAND, 131I-6β-iodomethyl-19norcholest-5(10)-en-3β-ol (131I-adosterol)1 was developed in the 1970s. Increased uptake of the agent in tumor regardless of visualization of the contralateral gland suggests that the adrenal mass is usually a benign cortical adenoma.2 This agent has the potency to diagnose lesions of the adrenal cortex and has been widely used to diagnose lesi...